Our Mission
Our Research

Working with
Patients in Mind

Our Mission

Beckley Psytech is dedicated to helping patients suffering from neurological and psychiatric disorders by developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines.

Sign up to our newsletter to keep up to date with our mission

Our Story

Our Research

Beckley Psytech’s primary aim is to help patients in need by developing psychedelic medicines that offer significant improvements over currently available neuropsychiatric treatments.

To that end, we are building a pipeline of psychedelic compounds with distinct clinical attributes for mental and neurological diseases. Our development programs will focus on offering innovation and clear differentiation in the marketplace over existing treatment options.

Our R&D platform can be divided into three distinct though interrelated categories:

  • 01

    “1st Generation” Psychedelic Medicine: Progressing innovative formulations and applications of well-characterised psychedelic agents such as psilocybin and other compounds

  • 02

    “2nd Generation” Psychedelic Medicine: Developing known but under-researched psychedelic agents with potential clinical and patient access advantages over the first wave of psychedelic medicines

  • 03

    “3rd Generation” Psychedelic Medicine: Designing New Chemical Entities (NCEs) that improve upon existing psychedelics by providing better clinical and cost-efficacy outcomes

Our Team

Our Story

For our founders, Lady Amanda Feilding and Cosmo Feilding Mellen, psychedelic medicines have been a lifelong and inter-generational vocation.

Amanda has dedicated over 50 years to the scientific exploration of psychedelics in the belief that modern science can be used to understand, validate, and optimise the healing potential of psychedelic medicines. In 1998 Amanda set up (and continues to run) the Beckley Foundation, a non-profit NGO focused on evidence-based drug policy reform and scientific research into psychedelic medicines.

Over the last 20 years the Beckley Foundation has become a world-famous pioneer in psychedelic research. Amanda has been dubbed “the hidden hand” behind the renaissance in psychedelic science, featured on the Guardian’s list of the Bravest Men and Women in the History of Science, and has personally co-authored over 50 peer-reviewed scientific publications on the subject, many with ground-breaking results.

Highlights of the Beckley Foundation’s work include:

  • 1998

    Study on psychedelics and cerebral circulation

  • 2007

    First Ethics Committee approval of LSD study since prohibition

  • 2009

    Beckley-Imperial Psychedelic Research Program

  • 2011

    Global public letter for Drug Policy Reform

  • 2012

    First ever brain imaging study on psilocybin

  • 2014

    First ever brain imaging study on LSD

  • 2014

    Psilocybin Tobacco Addiction Study

  • 2016

    Psilocybin Treatment Resistant Depression

  • 2017

    Ayahuasca Neurogenesis study

  • 2018

    LSD Microdosing study

Beckley Psytech was created to build upon the Foundation’s work by developing safe and effective psychedelic medicines available to patients in need and integrating these treatments into mainstream medical practice.

Beckley Psytech has a close strategic partnership with the Beckley Foundation and, in addition to its own pipeline, will provide financial and technical support to develop the Foundation’s most promising research. The company is committed to improving the lives of patients in need and will donate a share of future revenues to fund the non-profit work of the Foundation.

Highlights of the Beckley Foundation’s work include:

  • 1998

    Study on psychedelics and cerebral circulation

  • 2007

    First Ethics Committee approval of LSD study since prohibition

  • 2009

    Beckley-Imperial Psychedelic Research Program

  • 2011

    Global public letter for Drug Policy Reform

  • 2012

    First ever brain imaging study on psilocybin

  • 2014

    First ever brain imaging study on LSD

  • 2014

    Psilocybin Tobacco Addiction Study

  • 2016

    Psilocybin Treatment Resistant Depression

  • 2017

    Ayahuasca Neurogenesis study

  • 2018

    LSD Microdosing study

Contact Us

Contact Us

General enquiries — info@beckleypsytech.com
Media enquiries — beckley@fourcommunications.com

Subscribe to our newsletter

Keep up to date with the latest news and information

Back to top